Pharsight

Selzentry generic

Selzentry is an anti-HIV drug owned by Viiv Healthcare. It contains the active ingredient maraviroc. It was first authorized for market use on 4th November 2016, with a total of 3 patents, all of which have expired.

When will Selzentry generic be available?

The expiration of the last patent for Selzentry took place on 25th May 2023. This implies that the generic version of Selzentry could possibly be released after 30th April 2024.

Selzentry uses

Selzentry is primarily used in the treatment of patients infected with CCR5-tropic HIV-1. maraviroc, the active ingredient, contributes to the effectiveness of this drug.

Selzentry patent expiration

Selzentry has a total of three patents, all of which have expired. The most recent patent (US7368460*PED) expired on 25th May 2023. For more details about when a Selzentry generic could be available, check out the patent information below. Below are the details of the patents:

Selzentry dosage

Want to ask something?